Comparison of permeation enhancing strategies for an oral factor Xa inhibitor using the Caco-2 cell monolayer model

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 64, Issue 2, 2006, Pages 229-237

  Bruesewitz, Carsten ^a,b   Funke, Adrian ^a   Kuhland, Urte ^a   Wagner, Torsten ^a   Lipp, Ralph ^b,c  

^a BAYER PHARMA AG   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

BCS class III drug; Caco 2 cell culture; Chitosan; Efflux transporter; Factor Xa inhibitor; Intestinal permeability; Prodrugs

Indexed keywords

AMIDINE; BLOOD CLOTTING FACTOR 10A INHIBITOR; CHITOSAN; ESTER DERIVATIVE; ESTERASE; IMWITOR; PENETRATION ENHANCING AGENT; PRODRUG; QUINIDINE; UNCLASSIFIED DRUG; VERAPAMIL;

ARTICLE; CELL MEMBRANE PERMEABILITY; CELL STRAIN CACO 2; DRUG DETERMINATION; DRUG METABOLISM; DRUG PENETRATION; DRUG SOLUBILITY; HUMAN; HUMAN CELL; INTESTINE MUCOSA PERMEABILITY; IONIZATION; MEMBRANE PERMEABILITY; MOLECULAR WEIGHT; PROTEIN EXPRESSION;

ALGORITHMS; ANTITHROMBIN III; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; CHITOSAN; DRUG SYNERGISM; GLYCERIDES; HUMANS; MOLECULAR STRUCTURE; PROBENECID; PRODRUGS; QUINIDINE; SERINE PROTEINASE INHIBITORS; SPECTROPHOTOMETRY, ULTRAVIOLET; VERAPAMIL;

EID: 33747890546     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2006.05.012     Document Type: Article

References (31)

1. Amidon G.L., Lennernäs H., Shah V.P., and Crison J.R. A theoretical basis for a biopharmaceutics drug classification: the correlation of in vitro drug dissolution and in vivo bioavailability. Pharm. Res. 12 (1995) 413-420
2. Lipinski C.A., Lombardo F., Dominy B., and Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23 (1997) 3-25
3. Albert A. Cellular aspects of selective toxicity. Nature 182 (1958) 421-422
4. Bundgaard H. Design and application of prodrugs. In: Krogsgard-Larsen P., and Bundgaard H. (Eds). A Textbook of Drug Design and Development (1991), Harwood, Reading, UK 113-191
5. Artursson P., Ungell A.L., and Löfroth J.-E. Selective paracellular permeability in two models of intestinal absorption. Pharm. Res. 10 (1993) 1123-1129
6. Pade V., and Stavchansky S. Estimation of the relative contribution of the transcellular and paracellular pathway to the transport of passively absorbed drugs in the Caco-2 cell culture model. Pharm. Res. 14 (1997) 1210-1215
7. Artursson P., and Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2). Biochem. Biophys. Res. Commun. 175 (1991) 880-885
8. Karlsson J., Ungell A.-L., Grasjö J., and Artursson P. Paracellular drug transport across intestinal epithelia: influence of charge and induced water flux. Eur. J. Pharm. Sci. 9 (1999) 47-56
9. Lennernäs H. Human intestinal permeability. J. Pharm. Sci. 4 (1998) 403-410
10. a. In: van de Waterbeemd H., Lennernäs H., and Artursson P. (Eds). Drug Bioavailability (2003), Wiley-VCH, Weinheim, Germany 22-26
11. Vieth M., Siegel M.G., Higgs R.E., Watson I.A., Robertson D.H., Savin K.A., Durst G.L., and Hipskind P.A. Characteristic physical properties and structural fragments of marketed oral drugs. J. Med. Chem. 47 (2004) 224-232
12. Clement B., and Lopian K. Characterisation of in vitro biotransformation of new, orally active, direct thrombin inhibitor ximelagatran, an amidoxime and ester prodrug. Drug Metab. Dispos. 5 (2003) 645-651
13. Constantinides P.P., Scalart J.-P., Lancaster C., Marcello J., Marks G., Ellens H., and Smith P.L. Formulation and intestinal absorption enhancement evaluation of water-in-oil microemulsions incorporating medium chain glycerides. Pharm. Res. 11 (1994) 1385-1390
14. Hastewell J., Lynch S., Fox R., Williamson I., Skelton-Stroud P., and Mackay M. Enhancement of human calcitonin absorption across rat colon in vivo. Int. J. Pharm. 101 (1994) 115-120
15. Artursson P., Lindmark T., Davis S.S., and Illum L. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm. Res. 11 (1994) 1358-1361
16. Thanou M., Verhoef J.C., and Junginger H.E. Oral drug absorption enhancement by chitosan and its derivatives. Adv. Drug Deliv. Rev. 52 (2001) 117-126
17. Bernkop-Schnürch A., Krauland A.H., Leitner V.M., and Palmberger T. Thiomers: potential excipients for non-invasive peptide delivery systems. Eur. J. Pharm. Biopharm. 58 (2004) 253-263
18. Arzneimittel-Telegramm, 33 (2002) 3-4.
19. A.-M. Vangsted, Indikation of the Danish Medicines Agency on 14th of April, 2005.
20. Schipper N.G.M., Varum K.M., and Artursson P. Chitosans as absorption enhancers for poorly absorbable drugs: influence of molecular weight and degree of acetylation on drug transport across human intestinal epithelial (Caco-2) cells. Pharm. Res. 13 (1996) 1686-1692
21. Schipper N.G.M., Varum K.M., and Artursson P. Chitosans as absorption enhancers for poorly absorbable drugs: Mechanism of absorption enhancement. Pharm. Res. 14 (1997) 923-929
22. Benet L.Z., and Cummings C.L. The drug efflux-metabolism alliance: biochemical aspects. Adv. Drug Dev. Rev. 50 (2001) S3-S11
23. Kamm W., Hauptmann J., Behrens I., Stürzebecher J., Dullweber F., Golke H., Stubbs M., Klebe G., and Kissel T. Transport of peptidomimetik thrombin inhibitors with a 3-amidino-phenylalanine structure: permeability and efflux mechanism in monolayers of human intestinal cell line (Caco-2). Pharm. Res. 18 (2001) 1110-1118
24. Tsuoro T., and Tomida A. Multidrug resistance. Anti-Cancer Drugs 6 (1995) 213-218
25. Twentyman P.R., and Versantvoort C.H. Experimental modulation of MRP mediated resistance. Eur. J. Cancer 32 (1996) 1002-1009
26. Bourdet D.L., Pritchard J.B., and Thakker D.R. Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter hOCT1, hOCT2, hOCT3. J. Pharmacol. Exp. Ther. 315 (2005) 1288-1297
27. Sun D., Lennernäs H., Welage L.S., Barnett J.L., Landowski C.P., Foster D., Fleisher D., Lee K.-D., and Amidon G.L. Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharm. Res. 19 (2002) 1400-1416
28. Prueksaritanont T., Gorham L.M., Hochman J.H., Tran L., and Vyas K.P. Comparative studies of drug metabolising enzymes in dog, monkey and human small intestines and in Caco-2 cells. Drug Metab. Disp. 24 (1996) 634-642
29. Wagner C.A., Lükewille U., Kaltenbach S., Moschen I., Bröer A., Risler T., Bröer S., and Lang F. Functional and pharmacological characterization of the human Na+/carnitine cotransporter hOCTN2. Am. J. Physiol. Renal Physiol. 279 (2000) 584-591
30. Xia W.J., and Onyuksel H. Mechanistic studies on surfactant-induced membrane permeability enhancement. Pharm. Res. 17 (2000) 612-618
31. Bemporad D., Luttmann C., and Essex J.W. Behaviour of small solutes and large drugs in a lipid bilayer from computer simulations. Biochim. Biophys. Acta 1718 (2005) 1-21